Clinical Focus


  • Hematology
  • Pediatric Hematology-Oncology

Academic Appointments


Professional Education


  • Board Certification: American Board of Pediatrics, Pediatric Hematology-Oncology (2021)
  • Medical Education: University of Southern California Keck School of Medicine (2010) CA
  • Fellowship: Stanford University Pediatric Hematology Oncology Fellowship (2020) CA
  • Fellowship: Stanford University Hematology and Oncology Fellowship (2020) CA
  • Board Certification: American Board of Internal Medicine, Hematology (2019)
  • Board Certification: American Board of Pediatrics, Pediatrics (2014)
  • Board Certification: American Board of Internal Medicine, Internal Medicine (2014)
  • Residency: LACplusUSC Internal Medicine and Pediatric Residency (2014) CA

2022-23 Courses


All Publications


  • Longitudinal study of 2 patients with cyclic thrombocytopenia, STAT3, and MPL mutations. Blood advances Zhang, H., Chien, M., Hou, Y., Shomali, W., Brar, R., Ho, C., Han, P., Xu, D., Zhang, B. M., Guo, X., Tolentino, L., Wu, N. C., Tsai, A. G., Jin, J., Witteles, W. H., Chen, Z., Abidi, P., Jangam, D., Krieger, M. S., Craig, M., Bussel, J. B., Gotlib, J. R., Zehnder, J. L. 2022

    Abstract

    Cyclic thrombocytopenia (CTP) is a rare disease of periodic platelet count oscillations. The pathogenesis of CTP remains elusive. To study the underlying pathophysiology and genetic and cellular associations with CTP, we applied systems biology approaches to two patients with stable platelet cycling and reciprocal thrombopoietin (TPO) cycling at multiple time points through 2 cycles. Blood transcriptome analysis revealed cycling of platelet-specific genes, which are in parallel with and precede platelet count oscillation, indicating that cyclical platelet production leads platelet count cycling in both patients. Additionally, neutrophil and erythrocyte-specific genes also showed fluctuations correlating with platelet count changes, consistent with TPO effects on hematopoietic progenitors. Moreover, we found novel genetic associations with CTP. One patient had a novel germline heterozygous loss-of-function (LOF) thrombopoietin receptor (MPL) c.1210G>A mutation, and both had pathogenic somatic gain-of-function (GOF) variants in signal transducer and activator of transcription 3 (STAT3). In addition, both patients had clonal T-cell populations that remained stable throughout platelet count cycles. These mutations and clonal T cells may potentially involve in the pathogenic baseline in these patients rendering exaggerated persistent thrombopoiesis oscillations of their intrinsic rhythm upon homeostatic perturbations. This work provides new insights into the pathophysiology of CTP and possible therapies.

    View details for DOI 10.1182/bloodadvances.2021006701

    View details for PubMedID 35381066

  • Therapy-related myeloid neoplasms resembling juvenile myelomonocytic leukemia: a case series and review of the literature. Pediatric blood & cancer Wintering, A., Smith, S., Fuh, B., Rangaswami, A., Dahl, G., Chien, M., Gruber, T. A., Dang, J., Li, L. S., Lenzen, A., Savelli, S., Dvorak, C. C., Agrawal, A. K., Stieglitz, E. 1800: e29499

    Abstract

    Therapy-related myeloid neoplasms (t-MN) are a distinct subgroup of myeloid malignancies with a poor prognosis that include cases of therapy-related myelodysplastic syndrome (t-MDS), therapy-related myeloproliferative neoplasms (t-MPN) and therapy-related acute myeloid leukemia (t-AML). Here, we report a series of patients with clinical features consistent with juvenile myelomonocytic leukemia (JMML), an overlap syndrome of MDS and myeloproliferative neoplasms that developed after treatment for another malignancy.

    View details for DOI 10.1002/pbc.29499

    View details for PubMedID 34939322

  • Pediatric acquired factor VIII deficiency presenting as hemarthrosis. Pediatric blood & cancer Daigh, L. H., Chien, M. C., Lo, C. Y. 1800: e29530

    View details for DOI 10.1002/pbc.29530

    View details for PubMedID 34913591

  • Lentiviral Mediated Gene Therapy for Pyruvate Kinase Deficiency: Interim Results of a Global Phase 1 Study for Adult and Pediatric Patients Shah, A. J., Lopez Lorenzo, J., Navarro, S., Sevilla, J., Llanos, L., Perez de Camino Gaisse, B., Sanchez, S., Glader, B., Chien, M., Quintana Bustamante, O., Beard, B. C., Law, K. M., Zeini, M., Choi, G., Nicoletti, E., Rao, G. R., Grazia Roncarolo, M., Bueren, J. A., Schwartz, J. D., Segovia, J. C. AMER SOC HEMATOLOGY. 2021
  • Lentiviral Mediated Gene Therapy for Pyruvate Kinase Deficiency: Updated Results of a Global Phase 1 Study for Adult and Pediatric Patients Lopez Lorenzo, J., Shah, A. J., Navarro, S., Sevilla, J., Llanos, L., Perez Camino de Gaisse, B., Sanchez, S., Glader, B., Chien, M., Quintana-Bustamante, O., Beard, B. C., Law, K. M., Zeini, M., Choi, G., Nicoletti, E., Rao, G. R., Roncarolo, M., Bueren, J. A., Schwartz, J. D., Segovia, J. C. CELL PRESS. 2021: 42-43
  • A challenging case of recurrent idiopathic hemophagocytic lymphohistiocytosis (HLH) initially presenting in an infant with Pneumocystis jirovecii pneumonia Solomon, B., Balagtas, J., Chien, M., Pooni, R., Balboni, I., Weinacht, K., Gernez, Y. SPRINGER/PLENUM PUBLISHERS. 2021: S55
  • A Blueprint for Identifying Phenotypes and Drug Targets in Complex Disorders with Empirical Dynamics. Patterns (New York, N.Y.) Krieger, M. S., Moreau, J. M., Zhang, H., Chien, M., Zehnder, J. L., Craig, M. 2020; 1 (9): 100138

    Abstract

    A central challenge in medicine is translating from observational understanding to mechanistic understanding, where some observations are recognized as causes for the others. This can lead not only to new treatments and understanding, but also to recognition of novel phenotypes. Here, we apply a collection of mathematical techniques (empirical dynamics), which infer mechanistic networks in a model-free manner from longitudinal data, to hematopoiesis. Our study consists of three subjects with markers for cyclic thrombocytopenia, in which multiple cells and proteins undergo abnormal oscillations. One subject has atypical markers and may represent a rare phenotype. Our analyses support this contention, and also lend new evidence to a theory for the cause of this disorder. Simulations of an intervention yield encouraging results, even when applied to patient data outside our three subjects. These successes suggest that this blueprint has broader applicability in understanding and treating complex disorders.

    View details for DOI 10.1016/j.patter.2020.100138

    View details for PubMedID 33336196

  • Lentiviral Mediated Gene Therapy for Pyruvate Kinase Deficiency: A Global Phase 1 Study for Adult and Pediatric Patients Lorenzo, J., Navarro, S., Shah, A. J., Roncarolo, M., Sevilla, J., Llanos, L., de Gaisse, B., Sanchez, S., Glader, B., Chien, M., Bustamante, O., Beard, B. C., Law, K. M., Zeini, M., Choi, G., Nicoletti, E., Bueren, J. A., Rao, G. R., Schwartz, J. D., Segovia, J. C. AMER SOC HEMATOLOGY. 2020
  • Impact of in utero transfusions in fetuses with hydrops fetalis due to alpha thalassemia Lianoglou, B. R., Gonzalez, V., Velez, J., Norton, M. E., Chen, B., Finley, B., Hirata, G., Ogasawara, K., MacKenzie, T. C., Brown, R. N., Sanchez-Embrey, E., Shaw, S. W., Foe, M., Bitanga, M., Chien, M., Stumbaugh, T., Thompson, A. A., Viprakasit, V., Volanakis, E. J., Vichinsky, E. MOSBY-ELSEVIER. 2020: S300–S301
  • CLINICAL OUTCOME OF HB KHARTOUM/beta THALASSEMIA COMPOUND HETEROZYGOSITY: A GLIMPSE INTO HOMOZYGOUS HB KHARTOUM Chien, M., Glader, B. WILEY. 2018
  • ANTICOAGULATION FOR TREATMENT OF PAIN IN VENOUS MALFORMATIONS Chien, M., Kreimer, S., Teng, J., Marqueling, A., Jeng, M. WILEY. 2018